Phesgo and Tecentriq Performance and Approvals

Q1 2023: Highlights Sales Group sales decline of -3% resulting from erosion of COVID-19 related sales Solid Pharma and Diagnostics underlying business growth Currency impact on sales • Negative currency impact of -4%p primarily by the JPY, EUR and CNY Growth rates at CER (Constant exchange Rates) Roche 44

View entire presentation